Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

ASH 2024

7 - 10 Dec 2024

San Diego Convention Center, San Diego, United States of America

Krdc as induction therapy shows improved OS for NDMM patients

Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK

Krdc as induction therapy shows improved OS for NDMM patients ( Dr Charlotte Pawlyn - Institute of Cancer Research, London, UK )

Epcoritamab monotherapy is well tolerated and efficacious in patients with R/R...

Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA

Epcoritamab monotherapy is well tolerated and efficacious in patients with R/R CLL ( Dr Alexey Danilov - City of Hope National Medical Center, Los Angeles, USA )

Targeted therapies associated with increased risk for and incidence of...

Dr James Martin - Cleveland Clinic, Cleveland, USA

Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer ( Dr James Martin - Cleveland Clinic, Cleveland, USA )

Teclistamab-lenalidomide and teclistamab alone can be safely administered as...

Dr Elena Zamagni - University of Bologna, Bologna, Italy

Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus...

Dr Adam Olszewski - Brown University, Providence, USA

Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL ( Dr Adam Olszewski - Brown University, Providence, USA )

Acalabrutinib plus venetoclax with or without obinutuzumab versus...

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA

Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )

Primary IVIG supplementation reduces the risk of high-grade infections in...

Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA

Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy ( Heloise Cheruvalath - Medical College of Wisconsin, Milwaukee, USA )

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows...

Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA

Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma ( Dr Paolo Caimi - Cleveland Clinic, Cleveland, USA )

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced...

Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA

Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM ( Dr Peter Abdelmessieh - Fox Chase Cancer Center, Philadelphia, USA )

Pembrrolizumab after chemotherapy demonstrates promising activity and...

Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany

Pembrrolizumab after chemotherapy demonstrates promising activity and manageable safety in patients with low-risk cHL ( Prof Christine Mauz-Koerholz - Justus Liebig University, Giessen, Germany )

Analysis of pre-treatment biomarkers associated with toxicity and durable...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene...

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy

Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy ( Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA )

Teclistamab-based induction regimens demonstrate manageable safety and efficacy...

Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany

Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM ( Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany )

Addition of tafasitamab to lenalidomide plus rituximab significantly improves...

Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma ( Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA )

Blinatumomab added to chemotherapy improves disease-free survival in newly...

Dr Rachel Rau - University of Washington, Seattle, USA

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML...

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

IDH2 mutation associated with favourable outcome in older adults with newly...

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

Demographics, characteristics, survival and outcomes in older, untreated, AML...

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

Beat AML master trial update: A clinical trial for acute myeloid leukaemia

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA

Beat AML master trial update: A clinical trial for acute myeloid leukaemia ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )

Impact of MRD on progression-free survival in MM patients treated with...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

More from ecancer